Future developments and new research in genitourinary cancers. Perspectives.
Significant advances in the therapy of genitourinary cancers have occurred, yet the challenge of metastatic disease in many of these tumors remains unsolved. The great success achieved in the treatment of testicular cancer has been in large part due to the development of effective systemic therapy. Effective treatment for metastatic transitional cell carcinoma is just beginning to be described. Advanced renal and prostatic carcinomas remain a major clinical problem with no effective curative therapy. Novel new approaches to systemic therapy developed on sound basic experimental principles are needed. Several potential approaches such as angiogenesis factor, interleukin II, lymphokine activated killer cells, and tumor necrosis factor are discussed.
D043925:Angiogenesis Inducing Agents / Q000494:pharmacology; D000818:Animals; D002470:Cell Survival / Q000187:drug effects; D005260:Female; D005544:Forecasting; D006023:Glycoproteins / Q000494:pharmacology; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology; D007680:Kidney Neoplasms / Q000628:therapy; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011471:Prostatic Neoplasms / Q000628:therapy; D014409:Tumor Necrosis Factor-alpha; D014565:Urogenital Neoplasms / Q000473:pathology / Q000628:therapy*
D043925:Angiogenesis Inducing Agents; D006023:Glycoproteins; D007376:Interleukin-2; D014409:Tumor Necrosis Factor-alpha